◈ Madison Heights, MI · 2022

WhereScienceMeets Hope.

Veritas Clinical Research exists for one reason: to get it right. We conduct clinical trials with an uncompromising dedication to honest science and ethical principles — because the future of medicine depends on research the world can trust. No shortcuts. No spin. Just rigorous, transparent, patient-centered research that moves medicine forward.

Anatomically detailed pair of human lungs, breathing
Years of servicesince 2022

More than 20 years of pulmonary medicine behind every protocol.

◈ Our method

A rhythm of rigor — on every visit.

Every protocol we run anchors on the same three disciplines: careful phenotyping at baseline, standardized spirometry at every visit, and close follow-up for as long as the protocol requires.

Learn more about our team →

Seventeen trials. Two enrolling now.

Our full portfolio as a Principal Investigator site — asthma, COPD, IPF, and bronchiectasis, from Phase II to Phase IV. Recruiting studies accept direct volunteer referrals; screening is free and travel is reimbursed.
RecruitingNCT07190209

Lunsekimig vs. placebo in inadequately controlled eosinophilic COPD

Phase IIICOPD
View details →
RecruitingNCT07868419

Nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis (OCEAN-2)

Phase IIIIPF
View details →
Not yet recruitingNCT07780643

Felcorekibart (GSK5784283) as add-on therapy in uncontrolled asthma (PERSIST ASTHMA-1)

Phase IIIAsthma
View details →
Active · not recruitingNCT07793409

Long-term extension of lunsekimig, including inhaled corticosteroid withdrawal, in COPD

Phase IIICOPD
View details →
Active · not recruitingNCT07547436

SAR445399 in adults with non-cystic-fibrosis bronchiectasis

Phase IIBronchiectasis
View details →
Active · not recruitingNCT06748053

Dose-finding study of an anti-TSLP antibody (GSK5784283) in uncontrolled asthma

Phase IIAsthma
View details →
Active · not recruitingNCT05748600

Dexpramipexole in adolescents and adults with eosinophilic asthma

Phase IIIAsthma
View details →
Active · not recruitingNCT03953300

Benralizumab airway remodeling study in severe eosinophilic asthma

Phase IVAsthma
View details →
Active · not recruitingNCT06372496

FF/UMEC/VI vs. non-Ellipta usual-care ICS-LABA in uncontrolled asthma

Phase IVAsthma
View details →
CompletedNCT06208306

Long-term safety and tolerability of itepekimab in COPD

Phase IIICOPD
View details →
CompletedNCT04718389

Depemokimab (GSK3511294) vs. mepolizumab or benralizumab in severe eosinophilic asthma

Phase IIIAsthma
View details →
CompletedNCT04701983

Efficacy, safety, and tolerability of itepekimab (SAR440340/REGN3500) in COPD

Phase IIICOPD
View details →
CompletedNCT05326412

Mechanistic study of itepekimab on airway inflammation in COPD

Phase IICOPD
View details →
CompletedNCT06335303

BI 1819479 for improvement of lung function in idiopathic pulmonary fibrosis (IPF)

Phase IIIPF
View details →
CompletedNCT06280391

Itepekimab (anti-IL-33 mAb) proof-of-concept in non-cystic-fibrosis bronchiectasis

Phase IIBronchiectasis
View details →
TerminatedNCT05813288

Dexpramipexole in adolescents and adults with severe eosinophilic asthma (EXHALE-3)

Phase IIIAsthma
View details →
TerminatedNCT06360094

BI 1839100 for cough in idiopathic or progressive pulmonary fibrosis

Phase IIIPF / PPF
View details →
Dr. Franco Parodi, Principal Investigator at Veritas Clinical Research
◈ Principal investigator

Dr. Franco Parodi

EducationUniversidad de San Martin de Porres, Lima, Peru · Henry Ford Hospital, Detroit — Internal Medicine Residency & Fellowship in Pulmonary Diseases and Critical Care Medicine
MembershipsFellow of the American College of Chest Physicians · Member of the Association of Clinical Research Professionals
AppointmentsAssociate Professor of Medicine, Michigan State University College of Osteopathic Medicine · Associate Program Director, Fellowship in Pulmonary & Critical Care Medicine, Henry Ford Warren Hospital, MI
At Veritas Clinical Research, our work begins and ends with people. We are a clinical research site dedicated to advancing the future of medicine through carefully conducted clinical trials — driven not by shortcuts, but by a genuine commitment to truth and ethical responsibility. We believe every participant in our studies deserves transparency, respect, and care, and that every sponsor deserves research they can trust. By holding ourselves to the highest standards of scientific and moral integrity, we help bring tomorrow's most promising therapies safely and confidently into the world.
Franco Parodi, MD, FCCP, ACRP
Founder and PI
◈ What being a volunteer feels like

Four careful steps.

We don't believe in mystery. Here is exactly what happens from the first phone call to the last follow-up visit — with the option to stop at any step, no questions asked.

i

Conversation, not commitment

A call of about 20 minutes with a Veritas Clinical Research coordinator. We describe the trial, you describe your story, and we check whether there's a mutual fit.

Day 01
ii

Screening visit

Spirometry, bloodwork, medication review. You leave with a full copy of your pulmonary workup — whether you enroll or not.

Week 01
iii

Treatment phase

Regular visits on a predictable cadence. Our coordinator is one text away, every weekday.

Weeks 02–48
iv

Long-term follow-up

Optional annual visits up to five years, so the science — and your health — keeps moving forward together.

Years 1–5
◈ Start here

Let's breathe forward.

Whether you're a pulmonologist with a patient to refer, a sponsor evaluating sites, or a volunteer considering a trial — a single conversation starts the whole thing.

See if you qualify →Talk to a coordinator